SCHEMBL29660334

SCHEMBL29660334

CCOc1ccc(-c2nc(C(=O)OC(C)(C)C)c(C(=O)C(C)C)s2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 1/20 0.44
PTPN11 Q06124 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
TRPM8 Q7Z2W7 5/20 0.40
MAPT P10636 5/20 0.39
KDM4E B2RXH2 3/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HSP90AA1 P07900 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
HIF1A Q16665 1/20 0.39
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALPL P05186 1/20 0.38
ALPI P09923 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29660409 0.88 MAPT (0.46) TARBP2PTPN11TRPM8MAPTKDM4E
SCHEMBL29660360 0.84 TARBP2 (0.41) TARBP2PTPN11L3MBTL1MAPTKDM4E
SCHEMBL29660337 0.83 KDM4E (0.42) TARBP2PTPN11L3MBTL1TRPM8MAPT
SCHEMBL29660317 0.82 PTPN11 (0.44) PTPN11L3MBTL1TRPM8MAPTKDM4E
SCHEMBL29660324 0.82 MAPT (0.42) PTPN11MAPTKDM4ERAB9ASMN1; SMN2
SCHEMBL29660299 0.82 HSD17B10 (0.40) TARBP2PTPN11L3MBTL1TRPM8MAPT
SCHEMBL29660340 0.80 MAPT (0.40) PTPN11MAPTKDM4ERAB9ASMN1; SMN2
SCHEMBL29660346 0.77 MAPT (0.42) PTPN11L3MBTL1MAPTKDM4ERAB9A
SCHEMBL29660332 0.77 MMP13 (0.39) TARBP2PTPN11L3MBTL1MAPTKDM4E
SCHEMBL29911091 0.77 MAPT (0.41) L3MBTL1MAPTKDM4ERAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289698-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-09-15 US disclosed
EP-4003955-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289698-A1 INHIBITORS OF HUMAN ATGL LIPC, LIPG, PNLIP TARBP2 1082/4885PTPN11 2458/4885L3MBTL1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.